Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

New Preclinical and Clinical Approaches to Mesothelioma

New Preclinical and Clinical Approaches to Mesothelioma, an Archetypal Inflammatory Tumor

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study protocol involves the coordination between UO1 (IRCCS San Raffaele Hospital) and UO2 (Istituto Nazionale Tumori di Napoli - IRCCS G. Pascale) to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis. UO1 focuses on the role of HMGB1 in inflammation, mesothelioma progression, and tissue repair, as well as developing, in future, possible HMGB1 inhibitors for cancer therapy. UO2 specializes in CXCR4's role in cancer, developing CXCR4 antagonists, and tracking CXCR4-dependent metastasis. The hypothesis is that targeting HMGB1 and CXCR4 pathways will inhibit tumor progression and metastasis, enhancing anti-tumor immunity and improving therapeutic outcomes in cancer.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients with Mesothelioma: Clinical suspicion or diagnosed by tissue sample (biopsy-confirmed) diagnosis of pleural mesothelioma. - Candidates for surgical intervention. - Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well as breastfeeding women. - Capacity to comprehend the study nature and provide autonomously willing to sign a consent form. Control Group patients: - Absence of pleural mesothelioma but presence of other diagnosed by tissue sample (biopsy-confirmed) diseases (neoplastic, inflammatory, or infectious). - Candidates for surgical intervention. - Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well breastfeeding women. - Ability to understand the study nature and provide autonomously willing to sign a consent form. If the patient's diagnosis, whether provisional or definitive, does not confirm the clinical suspicion, they will not undergo further evaluation in the study. Who Should NOT Join This Trial: - Lack of biopsy material. - pregnancy. - Unwillingness to sign the willing to sign a consent form. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients with Mesothelioma: Clinical suspicion or histologically confirmed diagnosis of pleural mesothelioma. * Candidates for surgical intervention. * Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well as breastfeeding women. * Capacity to comprehend the study nature and provide autonomously informed consent. Control Group patients: * Absence of pleural mesothelioma but presence of other histologically confirmed diseases (neoplastic, inflammatory, or infectious). * Candidates for surgical intervention. * Age 18 years or older. It is possible to include both male and female patients, male and female patients of reproductive age, as well breastfeeding women. * Ability to understand the study nature and provide autonomously informed consent. If the patient's diagnosis, whether provisional or definitive, does not confirm the clinical suspicion, they will not undergo further evaluation in the study. Exclusion Criteria: * Lack of biopsy material. * pregnancy. * Unwillingness to sign the Informed Consent.

Locations (2)

Istituto Nazionale Tumori IRCCS Fondazione G.Pascale
Naples, Campania, Italy
IRCCS San Raffaele
Milan, Lombardy, Italy